New drug cocktail targets tough colorectal cancer

NCT ID NCT06356597

Ongoing Disease control Sponsor: Jing-yuan Fang, MD, Ph. D Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a combination of three drugs—Tislelizumab, Fruquintinib, and Metronidazole—in 33 adults with advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if this mix can slow cancer growth and improve survival. Participants must have a specific type of cancer (MSS or MSI-L) and high levels of a certain bacteria in their stool.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tislelizumab (a drug that helps the immune system fight cancer) combined with Fruquintinib (a drug that blocks blood vessel growth to tumors) and Metronidazole (an antibiotic)
What this could lead to: If this works, it could offer a new treatment option for people with advanced colorectal cancer that hasn't responded to standard therapies.
What could go wrong: This is a small, early Phase 2 trial with only 33 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

Shanghai First People's Hospital

Shanghai, China
Shanghai Ninth People's Hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.